Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: AAV factor IX gene therapy, Avigen Inc.

S A Fabb1, J G Dickson

  • 1Department of Biochemistry, Royal Holloway College, University of London, Egham, Surrey, TW20 OEX, UK. s.fabb@rhbnc.ac.uk

Current Opinion in Molecular Therapeutics
|March 16, 2001
PubMed
Summary

This gene therapy trial for hemophilia B used a novel viral vector to deliver Factor IX. Early results show it was safe and well-tolerated, with some patients experiencing clinical benefits.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Filariasis Among American Troops in a South Pacific Island Group.

The Yale journal of biology and medicine·2011
Same author

Gene therapy progress and prospects: Duchenne muscular dystrophy.

Gene therapy·2006
Same author

Recombinant micro-genes and dystrophin viral vectors.

Neuromuscular disorders : NMD·2002
Same author

Gene correction of the apolipoprotein (Apo) E2 phenotype to wild-type ApoE3 by in situ chimeraplasty.

The Journal of biological chemistry·2001
Same author

Allelic variation of ovine MHC class II DQA1 and DQA2 genes.

Animal genetics·1998
Same author

Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy.

Cell·1997

Area of Science:

  • Gene therapy
  • Hematology
  • Viral vector technology

Background:

  • Hemophilia B is a serious bleeding disorder caused by a deficiency in Factor IX.
  • Current treatments involve regular infusions of Factor IX concentrate.
  • Novel therapeutic approaches, including gene therapy, are needed to improve patient outcomes.

Purpose of the Study:

  • To evaluate the safety and preliminary efficacy of a recombinant adeno-associated viral vector (AAV-CMV-hF.IX) for hemophilia B treatment.
  • To assess potential toxicity, germline transmission, and immune responses to the vector and Factor IX.

Main Methods:

  • A Phase I clinical trial was conducted involving three patients with severe hemophilia B.
  • Patients received a low-dose injection of the AAV-CMV-hF.IX vector (Coagulin-B).

Related Experiment Videos

  • Safety assessments included monitoring for toxicity, germline transmission, and inhibitory antibodies.

    • Main Results:

    • The AAV-CMV-hF.IX vector was found to be safe and well-tolerated in all three patients.
    • No evidence of toxicity or germline transmission of vector sequences was observed.
    • Two of the three patients showed a modest clinical response, indicating potential therapeutic benefit.

    Conclusions:

    • This study demonstrates the preliminary safety and tolerability of AAV-CMV-hF.IX gene therapy for hemophilia B.
    • The observed clinical response suggests potential efficacy, warranting further investigation in larger trials.
    • Gene therapy represents a promising avenue for the treatment of hemophilia B.